The provided text is an auditor consent exhibit (EX-23.1) from Niagen Bioscience, Inc.'s Annual Report on Form 10-K, filed with the SEC. It contains consent from Crowe LLP for incorporation of audit reports into registration statements. No business description, products, or services are described in this excerpt.
Q2 FY2026 — expected 2026-08-17
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-04 | 2025-12-31 | 0001386570-26-000013 | EDGAR | 56K words |
| 2025-03-04 | 2024-12-31 | 0001628280-25-009774 | EDGAR | — |
| 2024-03-06 | 2023-12-31 | 0001628280-24-009380 | EDGAR | — |
| 2023-03-08 | 2022-12-31 | 0001628280-23-006968 | EDGAR | — |
| 2022-03-14 | 2021-12-31 | 0001628280-22-006041 | EDGAR | — |
| 2021-03-12 | 2020-12-31 | 0001654954-21-002692 | EDGAR | — |
| 2020-03-10 | 2019-12-31 | 0001654954-20-002437 | EDGAR | — |
| 2019-03-07 | 2018-12-31 | 0001654954-19-002395 | EDGAR | — |
| 2018-03-15 | 2017-12-30 | 0001654954-18-002621 | EDGAR | — |
| 2017-03-16 | 2016-12-31 | 0001654954-17-002092 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-04 | 2025-09-30 | 0001386570-25-000020 | EDGAR | 38K words |
| 2025-08-06 | 2025-06-30 | 0001386570-25-000010 | EDGAR | — |
| 2025-05-07 | 2025-03-31 | 0001628280-25-023127 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0001628280-24-044540 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0001628280-24-035591 | EDGAR | — |
| 2024-05-08 | 2024-03-31 | 0001628280-24-021645 | EDGAR | — |
| 2023-11-08 | 2023-09-30 | 0001628280-23-037809 | EDGAR | — |
| 2023-08-09 | 2023-06-30 | 0001628280-23-028551 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001628280-23-017204 | EDGAR | — |
| 2022-11-02 | 2022-09-30 | 0001628280-22-027803 | EDGAR | — |
| 2022-08-10 | 2022-06-30 | 0001628280-22-022216 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001628280-22-014057 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-19 | 0001386570-26-000017 | EDGAR | 1K words |
| 2026-03-04 | 0001386570-26-000014 | EDGAR | — |
| 2026-02-26 | 0001386570-26-000003 | EDGAR | — |
| 2025-12-22 | 0001386570-25-000030 | EDGAR | — |
| 2025-11-06 | 0001386570-25-000025 | EDGAR | — |
| 2025-11-04 | 0001386570-25-000021 | EDGAR | — |
| 2025-10-06 | 0001386570-25-000015 | EDGAR | — |
| 2025-08-06 | 0001386570-25-000011 | EDGAR | — |
| 2025-07-29 | 0001628280-25-036445 | EDGAR | — |
| 2025-06-27 | 0001628280-25-033302 | EDGAR | — |
353 total filings indexed. 321 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001386570 |
| Ticker | NAGE |
| Exchange | Nasdaq |
| SIC | 2833: Medicinal Chemicals & Botanical Products |
| Incorporated | DE |
| Headquarters | Costa Mesa, California |
| Website | https://www.niagenbioscience.com |
| Listed | 2008-06-24 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report